SCHEMBL5453022

SCHEMBL5453022

CN1CCc2cc(N(C)C)c(S(=O)(=O)c3ccc(Cc4ccc(OC(F)(F)F)cc4)cc3)cc2CC1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.46
SLC6A4 P31645 6/20 0.44
SLC6A3 Q01959 5/20 0.44
ALDH1A1 P00352 1/20 0.42
HTR6 P50406 3/20 0.40
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
HRH3 Q9Y5N1 1/20 0.37
KDM2B Q8NHM5 1/20 0.37
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MOGAT2 Q3SYC2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457191 0.92 CARM1 (0.38) HTR2ASLC6A4SLC6A3HRH3KDM2B
SCHEMBL5459209 0.88 DRD1 (0.43) HTR2ASLC6A4SLC6A3ALDH1A1USP2
SCHEMBL5467071 0.86 LMNA (0.43) HTR2AHRH3USP2SMN1; SMN2
SCHEMBL5445721 0.85 USP2 (0.41) HTR2AHTR6USP2SMN1; SMN2MOGAT2
SCHEMBL5453002 0.84 USP2 (0.42) HTR2AALDH1A1HTR6USP2SMN1; SMN2
SCHEMBL14411990 0.84 HTR6 (0.43) HTR2AHTR6HRH3USP2SMN1; SMN2
SCHEMBL5452773 0.84 USP2 (0.42) HTR2AHTR6USP2SMN1; SMN2
SCHEMBL5457597 0.83 USP2 (0.40) HTR2AHTR6USP2SMN1; SMN2MOGAT2
SCHEMBL5452896 0.83 HTR2C (0.42) HTR2AALDH1A1HTR6USP2SMN1; SMN2
SCHEMBL5462456 0.83 USP2 (0.41) HTR2ASLC6A4SLC6A3ALDH1A1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP disclosed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 HTR2A 448/4885SLC6A4 19/4885SLC6A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.